These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 17373735)

  • 21. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
    Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
    Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
    Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of fragile histidine triad in primary hepatocellular carcinoma and its relation with cell proliferation and apoptosis.
    Nan KJ; Ruan ZP; Jing Z; Qin HX; Wang HY; Guo H; Xu R
    World J Gastroenterol; 2005 Jan; 11(2):228-31. PubMed ID: 15633221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas.
    Luceri C; Guglielmi F; De Filippo C; Caderni G; Mini E; Biggeri A; Napoli C; Tonelli F; Cianchi F; Dolara P
    Scand J Gastroenterol; 2000 Jun; 35(6):637-41. PubMed ID: 10912665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.
    O'Driscoll L; Linehan R; M Kennedy S; Cronin D; Purcell R; Glynn S; W McDermott E; D Hill A; J O'Higgins N; Parkinson M; Clynes M
    Cancer Lett; 2003 Nov; 201(2):225-36. PubMed ID: 14607338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.
    Mori M; Mimori K; Masuda T; Yoshinaga K; Yamashita K; Matsuyama A; Inoue H
    Cancer Res; 2001 Oct; 61(20):7379-82. PubMed ID: 11606365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequent altered expression of fragile histidine triad protein in human colorectal adenomas.
    Morikawa H; Nakagawa Y; Hashimoto K; Niki M; Egashira Y; Hirata I; Katsu K; Akao Y
    Biochem Biophys Res Commun; 2000 Nov; 278(1):205-10. PubMed ID: 11071873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms.
    Yasugi A; Yashima K; Hara A; Koda M; Kawaguchi K; Harada K; Andachi H; Murawaki Y
    Oncol Rep; 2008 Jan; 19(1):41-7. PubMed ID: 18097574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression.
    Mimori K; Ishii H; Nagahara H; Sudo T; Yamashita K; Inoue H; Barnard GF; Mori M
    Cancer Res; 2006 Mar; 66(5):2683-90. PubMed ID: 16510588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
    McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of fragile histidine triad gene transduction on proliferation and apoptosis of human hepatocellular carcinoma cells.
    Xu RH; Zheng LY; He DL; Tong J; Zheng LP; Zheng WP; Meng J; Xia LP; Wang CJ; Yi JL
    World J Gastroenterol; 2008 Jun; 14(23):3754-8. PubMed ID: 18595145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.
    Zhao P; Liu W; Lu YL
    World J Gastroenterol; 2005 Sep; 11(36):5735-8. PubMed ID: 16237777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas.
    Krajewska M; Moss SF; Krajewski S; Song K; Holt PR; Reed JC
    Cancer Res; 1996 May; 56(10):2422-7. PubMed ID: 8625322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human colorectal carcinoma tissue.
    Yu LL; Yu HG; Yu JP; Luo HS; Xu XM; Li JH
    World J Gastroenterol; 2004 Nov; 10(22):3255-60. PubMed ID: 15484295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.
    Li H; Zhao P; Lu Y; Lu Y
    Int J Colorectal Dis; 2012 Aug; 27(8):1015-20. PubMed ID: 22315171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of Fhit expression in development of colorectal carcinoma of various macroscopic types.
    Kuwai T; Tanaka S; Kaio E; Hiyama T; Ito M; Kitadai Y; Sumii M; Yoshihara M; Haruma K; Chayama K
    Int J Mol Med; 2003 Oct; 12(4):437-42. PubMed ID: 12964015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survivin expression in colorectal adenocarcinoma using tissue microarray.
    Abd El-Hameed A
    J Egypt Natl Canc Inst; 2005 Mar; 17(1):42-50. PubMed ID: 16353082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of FHIT in salivary carcinoma ex pleomorphic adenoma.
    Kujan O; Tarakji B; Thakker N; Al Kheraif AA; Sloan P
    Anticancer Res; 2012 Aug; 32(8):3147-52. PubMed ID: 22843886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aberrant FHIT expression is linked to bladder carcinogenesis and apoptosis.
    Han Y; Zhang Z; Zhang GJ; Guo KF; Shan GY; Kong CZ
    Asian Pac J Cancer Prev; 2011; 12(11):2915-20. PubMed ID: 22393963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The significance of fragile histidine triad protein as a molecular prognostic marker of bladder urothelial carcinoma.
    Zhang CT; Lu R; Lin YL; Liu RL; Zhang ZH; Yang K; Dang RF; Zhang HT; Shen YG; Kong PZ; Ren HL; Li XL; Quan W; Xu Y
    J Int Med Res; 2012; 40(2):507-16. PubMed ID: 22613411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.